Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Efficacy and Safety of Erenumab (AMG 334) in Chronic Migraine Prevention

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* History of at least 5 attacks of migraine without aura and/or migraine with visual sensory, speech and/or language, retinal or brainstem aura.~* History of ≥ 15 headache days per month of which ≥ 8 headache days were assessed by the subject as migraine day.~* ≥ 4 distinct headache episodes, each lasting ≥ 4 hours OR if shorter, associated with use of a triptan or ergot-derivative on the same calendar day based on the eDiary calculations.~* Demonstrated at least 80% compliance with the eDiary.~Exclusion Criteria:~* History of cluster headache or hemiplegic migraine headache~* Unable to differentiate migraine from other headaches~* Failed \> 3 medication categories due to lack of efficacy for prophylactic treatment of migraine .~* Received botulinum toxinin head or neck region within 4 months prior to screening.~* Used a prohibited migraine prophylactic medication, device or procedure within 2 months prior to the start of the baseline phase

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Participants received placebo on day 1 and at weeks 4 and 8 by subcutaneous injection.
- Erenumab 70 mg (Type: EXPERIMENTAL): Participants received 70 mg erenumab on day 1 and at weeks 4 and 8 by subcutaneous injection.
- Erenumab 140 mg (Type: PLACEBO_COMPARATOR): Participants received 140 mg erenumab on day 1 and at weeks 4 and 8 by subcutaneous injection.

Based on this trial design, predict the completion outcome and termination type (if applicable).